PAREXEL Announces Master Services Agreement with Pfizer
June 10 2016 - 2:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced that it
has signed a services agreement with Pfizer Inc. Under the terms of
this agreement, PAREXEL will continue to provide global clinical
research and development services to Pfizer in support of clinical
development programs across its portfolio. Terms of the agreement
were not disclosed.
“PAREXEL will continue to leverage its proven clinical processes
and expertise to help Pfizer conduct clinical trials and accomplish
its drug development goals,” said Josef von Rickenbach, Chairman
and Chief Executive Officer, PAREXEL International. “Our team is
focused on applying dynamic and innovative operational models to
help Pfizer develop drugs to improve health and treat diseases for
patients around the world.”
As an innovator in creating strategic partnerships in the
biopharmaceutical services industry, PAREXEL uses a spectrum of
relationship models to meet the diverse requirements of clients.
This includes large companies as well as emerging companies through
its BioPharm unit. PAREXEL’s approach focuses on assisting
biopharmaceutical companies in reducing fixed costs, shortening
development times, and speeding delivery of safe and effective
treatments to market. PAREXEL has transformed its business to
deliver a new level of strategic services based on program design
expertise, operational excellence, and project leadership to help
clients achieve their development goals.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 82 locations in 51 countries around the
world, and had approximately 18,450 employees in the third quarter.
For more information about PAREXEL International, visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160609006535/en/
PAREXEL InternationalMedia:Cristi Barnett,
+1-781-434-4019Cristi.Barnett@PAREXEL.comorInvestors:Ron Aldridge,
+1-781-434-4753Ron.Aldridge@parexel.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Sep 2023 to Sep 2024